Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RDHL
stocks logo

RDHL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Redhill Biopharma Ltd (RDHL.O) is 0.02, compared to its 5-year average forward P/E of -7.31. For a more detailed relative valuation and DCF analysis to assess Redhill Biopharma Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.31
Current PE
0.02
Overvalued PE
4.86
Undervalued PE
-19.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.06
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.23
Undervalued EV/EBITDA
-6.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.23
Current PS
0.00
Overvalued PS
2.31
Undervalued PS
0.15
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RDHL News & Events

Events Timeline

(ET)
2025-11-04
12:04:03
RedHill Announces Finalization of $10.5M New York Supreme Court Judgment for Enforcement
select
2025-11-04
09:31:49
RedHill Biopharma Secures $10.5M Judgment Victory in New York Supreme Court
select
2025-10-20 (ET)
2025-10-20
09:03:44
RedHill Biopharma Enters Strategic Alliance with Cumberland
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01PRnewswire
RedHill Biopharma Regains Nasdaq Compliance with Stockholders' Equity Exceeding $2.5 Million
  • Compliance Regained: On November 26, 2025, RedHill Biopharma confirmed it has regained compliance with Nasdaq Listing Rule 5550(b)(1), demonstrating stockholders' equity exceeding $2.5 million, which marks a significant milestone in the company's strategic initiatives for 2025.
  • Strategic Partnership: The ongoing partnership with Cumberland Pharmaceuticals for Talicia® aims to enhance RedHill's competitive position in the U.S. market, which is expected to positively impact the company's financial standing and global business operations.
  • Operational Efficiency Focus: RedHill is concentrating on improving operational efficiency, intending to optimize internal processes and resource allocation to strengthen its market position in the biopharmaceutical sector, thereby laying a foundation for future growth.
  • Clinical Development Programs: The company is advancing multiple key clinical programs, including treatments for COVID-19 and other cancers and inflammatory diseases, demonstrating its ongoing commitment to innovative drug development.
[object Object]
Preview
9.5
12-01Newsfilter
RedHill Biopharma Regains Nasdaq Compliance with $2.5M Equity Requirement
  • Compliance Regained: On November 26, 2025, RedHill Biopharma confirmed it has met the Nasdaq Listing Rule 5550(b)(1) stockholders' equity requirement, successfully restoring compliance and ensuring the company's ongoing operations in the capital markets.
  • Strategic Partnership: The company continues to advance its partnership with Cumberland Pharmaceuticals for Talicia®, aimed at enhancing its competitive position in the U.S. market, particularly in treating Helicobacter pylori infections.
  • R&D Focus: RedHill is concentrating on several late-stage clinical development programs, including opaganib for COVID-19 and RHB-204 for Crohn's disease, demonstrating the company's ongoing commitment to innovative drug development.
  • Market Outlook: By regaining compliance, RedHill is better positioned to attract investor interest, strengthening its market position in the biopharmaceutical sector, especially regarding potential growth opportunities in gastrointestinal diseases and oncology.
[object Object]
Preview
7.0
11-04PRnewswire
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

  • Court Ruling in Favor of RedHill: The New York Supreme Court has issued a final summary judgment in favor of RedHill Biopharma against Kukbo Co. Ltd, awarding RedHill over $10.5 million, which includes approximately $8.6 million in damages and $1.9 million in legal fees.

  • Asset Protection Measures: RedHill has obtained a court attachment in Korea to prevent Kukbo from disposing of assets before the enforcement of the judgment.

  • Company Overview: RedHill Biopharma focuses on developing and commercializing drugs for gastrointestinal diseases, infectious diseases, and oncology, with key products including the FDA-approved Talicia® and several late-stage clinical programs.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and potential risks, emphasizing uncertainties in product development, regulatory approvals, and market acceptance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Redhill Biopharma Ltd (RDHL) stock price today?

The current price of RDHL is 1.2 USD — it has increased 2.56 % in the last trading day.

arrow icon

What is Redhill Biopharma Ltd (RDHL)'s business?

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

arrow icon

What is the price predicton of RDHL Stock?

Wall Street analysts forecast RDHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDHL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Redhill Biopharma Ltd (RDHL)'s revenue for the last quarter?

Redhill Biopharma Ltd revenue for the last quarter amounts to 1.80M USD, decreased -90.21 % YoY.

arrow icon

What is Redhill Biopharma Ltd (RDHL)'s earnings per share (EPS) for the last quarter?

Redhill Biopharma Ltd. EPS for the last quarter amounts to 0.01 USD, decreased -100.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for Redhill Biopharma Ltd (RDHL)'s fundamentals?

The market is revising No Change the revenue expectations for RDHL for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -16.29%.
arrow icon

How many employees does Redhill Biopharma Ltd (RDHL). have?

Redhill Biopharma Ltd (RDHL) has 35 emplpoyees as of December 05 2025.

arrow icon

What is Redhill Biopharma Ltd (RDHL) market cap?

Today RDHL has the market capitalization of 4.00M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free